MaxCyte, Inc. Issue of Equity and Total Voting Rights (8949K)
September 06 2021 - 12:21PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8949K
MaxCyte, Inc.
06 September 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Issue of Equity
Increase to Block Listing
Block Listing Return
and
Total Voting Rights
GAITHERSBURG, MD, September 6, 2021 - MaxCyte, Inc., (NASDAQ:
MXCT) (LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading
provider of cell-engineering platform technologies, announces that
the Company has issued 128,615 of new common stock of $0.01 each in
the capital of the Company ("Common Stock") pursuant to the recent
exercise of stock options and warrants. Of these new common stock,
64,012 common stock have been issued pursuant to the Company's
existing AIM block admission facility. Application has been made to
admission to trading on AIM of the remaining 64,603 Common Stock
("Admission") with Admission expected to occur on 10 September
2021. The new Common Stock above rank pari passu with the Company's
existing shares of Common Stock of the company.
A pplication has also been made for admission to trading on AIM
in respect of an additional block listing of 13 million Common
Stock to become effective on 10 September 2021 ("New Block
Listing"). Pursuant to the New Block Listing, Common Stock may be
issued pursuant to the exercise of share options under the
Company's Long-Term Incentive Plan (the "LTIP") and will, upon
issue, rank pari passu in all respects with the Company's existing
Common Stock. Following this increase, the total block listing will
consist of 13 million Common Stock.
AIM Block Admission Return
MaxCyte also makes the following update on its block listings,
pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies.
a. Name of company
MaxCyte, Inc.
b. Name of scheme(s)
MaxCyte Long Term Incentive Plan
c. Period of return:
From: 22 January 2021 To: 31 August 2021
d. Number and class of securities not issued under scheme
1,000,000 ordinary shares of common stock of $0.01 each
e. Number of shares issued under scheme during period
921,342 ordinary shares of common stock of $0.01 each
f. Balance under the scheme not yet issued at the end of the
period.
78,658 ordinary shares of common stock of $0.01 each
g. Number and class of share(s) (amount of stock / debt
securities) originally listed and the date of admission; If
additional block listing application have been made, under this
scheme, since the original listing application please also state
the number of shares and the date(s) of admission.
1,000,000 common stock of $0.01 each on 5 May 2017
942,900 common stock of $0.01 each on 27 January 2021
Please confirm your total issued share capital as at the end of
this period.
(If you hold any shares in Treasury state the figure
separately);
As at 31 August 2021, the total issued stock capital of the
Company is 100,388,418 shares of Common Stock. Shareholders in the
Company may use this figure as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the stock capital of
the Company.
Treasury shares (if applicable) .........Nil.............
h. Contact name and telephone number for queries;
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer
+1 301 944 1660
Date
6 September 2021
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies to advance innovative cell-based research, development
and potential commercialization of next-generation cell therapies.
The Company's existing customer base ranges from large
biopharmaceutical companies - including 20 of the top 25
pharmaceutical companies based on 2020 global revenue - to hundreds
of biotechnology companies and academic translational centers.
MaxCyte has granted 14 strategic platform licenses to commercial
cell therapy developers that allow for more than 75 clinical
programs. Founded in 1998, MaxCyte is headquartered in
Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew
O'Dowd +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira
Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
US Media Relations
Jamie Lacey-Moreira +1 410 299-3310
PressComm PR, LLC jamielacey@presscommpr.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKABDABKDACK
(END) Dow Jones Newswires
September 06, 2021 12:21 ET (16:21 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024